Late complications of the new coronavirus infection: a clinical case

Q4 Medicine

Pulmonologiya Pub Date : 2023-02-11 DOI:10.18093/0869-0189-2023-33-1-102-108

S. Chepurnenko, G. Shavkuta, A. Demidova

{"title":"Late complications of the new coronavirus infection: a clinical case","authors":"S. Chepurnenko, G. Shavkuta, A. Demidova","doi":"10.18093/0869-0189-2023-33-1-102-108","DOIUrl":null,"url":null,"abstract":"According to the literature, exudative pleurisy and pericarditis are considered rare complications of the new coronavirus infection. This estimation can be explained by the fact that statistical studies cover mainly the hospital treatment of this disease. The true frequency of these complications and their consequences are not fully understood.Aim. The study of late complications of the new coronavirus infection in the form of pleurisy and pericarditis.Conclusion. In our case, a 62-year-old patient with the new coronavirus infection confirmed by polymerase chain reaction, severe bilateral polysegmental viral pneumonia, CT3, 60% on day 43 after the onset of clinical symptoms, was found to have manifestations of pleurisy and pericarditis during outpatient treatment. Cardiac MRI is the most informative method for detecting small pericardial and pleural effusions. The diagnostic capabilities of this method are superior to ultrasounography of the heart and pleural cavities and computed tomography of the lungs. Administration of colchicine 1.0 g per day for 1 month allowed not only to the elimination of pericarditis and pleurisy, but also the reduction of pressure in the right ventricle, probably by reducing the damage to the pulmonary parenchyma.","PeriodicalId":37383,"journal":{"name":"Pulmonologiya","volume":"27 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18093/0869-0189-2023-33-1-102-108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

According to the literature, exudative pleurisy and pericarditis are considered rare complications of the new coronavirus infection. This estimation can be explained by the fact that statistical studies cover mainly the hospital treatment of this disease. The true frequency of these complications and their consequences are not fully understood.Aim. The study of late complications of the new coronavirus infection in the form of pleurisy and pericarditis.Conclusion. In our case, a 62-year-old patient with the new coronavirus infection confirmed by polymerase chain reaction, severe bilateral polysegmental viral pneumonia, CT3, 60% on day 43 after the onset of clinical symptoms, was found to have manifestations of pleurisy and pericarditis during outpatient treatment. Cardiac MRI is the most informative method for detecting small pericardial and pleural effusions. The diagnostic capabilities of this method are superior to ultrasounography of the heart and pleural cavities and computed tomography of the lungs. Administration of colchicine 1.0 g per day for 1 month allowed not only to the elimination of pericarditis and pleurisy, but also the reduction of pressure in the right ventricle, probably by reducing the damage to the pulmonary parenchyma.

查看原文本刊更多论文

新型冠状病毒感染晚期并发症1例

据文献报道，渗出性胸膜炎和心包炎被认为是新型冠状病毒感染的罕见并发症。这一估计可以通过统计研究主要涵盖该疾病的医院治疗这一事实来解释。这些并发症的真实频率及其后果尚不完全清楚。新型冠状病毒感染晚期并发症胸膜炎、心包炎的研究。本病例患者为62岁，经聚合酶链反应确诊为新型冠状病毒感染，重度双侧多节段性病毒性肺炎，CT3, 60%，出现临床症状后第43天，门诊就诊时发现胸膜炎、心包炎表现。心脏MRI是检测少量心包积液和胸腔积液最有效的方法。这种方法的诊断能力优于心脏和胸膜腔的超声检查和肺部的计算机断层扫描。每天服用秋水仙碱1.0 g，持续1个月，不仅可以消除心包炎和胸膜炎，还可以降低右心室的压力，可能是通过减少对肺实质的损害。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonologiya Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The aim of this journal is to state a scientific position of the Russian Respiratory Society (RRS) on diagnosis and treatment of respiratory diseases based on recent evidence-based clinical trial publications and international consensuses. The most important tasks of the journal are: -improvement proficiency qualifications of respiratory specialists; -education in pulmonology; -prompt publication of original studies on diagnosis and treatment of respiratory diseases; -sharing clinical experience and information about pulmonology service organization in different regions of Russia; -information on current protocols, standards and recommendations of international respiratory societies; -discussion and consequent publication Russian consensus documents and announcement of RRS activities; -publication and comments of regulatory documents of Russian Ministry of Health; -historical review of Russian pulmonology development. The scientific concept of the journal includes publication of current evidence-based studies on respiratory medicine and their discussion with the participation of Russian and foreign experts and development of national consensus documents on respiratory medicine. Russian and foreign respiratory specialists including pneumologists, TB specialists, thoracic surgeons, allergists, clinical immunologists, pediatricians, oncologists, physiologists, and therapeutists are invited to publish article in the journal.